Journal
JOURNAL OF DRUG TARGETING
Volume 18, Issue 3, Pages 205-211Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10611860903353362
Keywords
Blood-brain barrier; drug targeting; monoclonal antibody; lysosomal enzyme
Categories
Funding
- NIH [R44-HD052303]
Ask authors/readers for more resources
beta-Glucuronidase (GUSB) is a lysosomal enzyme that could be developed as a brain therapy for Type VII Mucopolysaccharidosis. However, GUSB does not cross the blood-brain barrier (BBB). To enable BBB transport of the enzyme, human GUSB was re-engineered as a fusion protein with the chimeric monoclonal antibody (MAb) to the human insulin receptor (HIR). The HIRMAb crosses the BBB on the endogenous insulin receptor, and acts as a molecular Trojan horse to ferry into brain the GUSB. The 611 amino acid GUSB was fused to either the carboxyl or amino terminus of the heavy chain of the HIRMAb. This study illustrates the differential retention of functionality of IgG-enzyme fusion proteins depending on how the fusion protein is engineered.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available